循环素依赖性酶9抑制降低了编程死亡链接1的表达,并改善了肝细胞癌的治疗疗效
Yu-Yun Shao1,2,3, Min-Shu Hsieh4,5,6, Yi-Hsuan Lee4,5
1Graduate Institute of Oncology, National Taiwan University College of Medicine, 1, Sec. 1, Ren'ai Rd., Taipei City, 10051, R.O.C, Taiwan.
Heliyon
|August 5, 2024
概括
循环素依赖性激酶9 (CDK9) 的抑制降低了肝癌细胞中编程死亡配体1 (PD-L1) 的表达. 将CDK9抑制剂与抗PD-L1抗体结合起来,为肝细胞癌提供了更有效的治疗策略.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 分子生物学分子生物学
背景情况:
- 反编程死亡配体1 (PD-L1) 抗体是晚期肝细胞癌 (HCC) 的标准.
- 瘤PD-L1表达可以通过刺激来诱导.
- 循环素依赖性激酶9 (CDK9) 的抑制降低了可诱导的蛋白质表达.
研究的目的:
- 为了研究CDK9抑制对HCC细胞PD-L1表达的影响.
- 评估结合CDK9抑制剂与HCC中抗PD-L1抗体的治疗潜力.
主要方法:
- 在HCC细胞中评估PD-L1表达.
- 使用了CDK9抑制剂 (AZD4573,阿图韦西克利布) 和CDK9抑制/过度表达.
- 在HCC的 ортотоп性小鼠模型中评估了组合疗法.
主要成果:
- IFN-γ治疗增加了HCC细胞中的PD-L1表达.
- CDK9抑制剂和敲击显著降低IFN-γ诱导的PD-L1表达.
- 在小鼠中,组合疗法导致了较小的瘤和更好的生存率.
结论:
- 抑制CDK9有效地降低了HCC细胞中的PD-L1表达.
- 将CDK9抑制剂与抗PD-L1抗体结合起来,与单独治疗相比,其疗效更高.
相关概念视频
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K


